Regulator clears clinical trials of Covaxin on children aged 2 to 18 years

Tribune Web Desk Chandigarh, May 13 National regulator Drugs Controller General of India (DCGI) has accepted the recommendation of the Subject Expert Committee (SEC) and accorded permission to conduct the phase-II/III clinical trials of Covaxin in the age group 2...

Tribune Web Desk

Updated At : 04:53 PM May 13, 2021 IST

Tribune Web Desk

Chandigarh, May 13

National regulator Drugs Controller General of India (DCGI) has accepted the recommendation of the Subject Expert Committee (SEC) and accorded permission to conduct the phase-II/III clinical trials of Covaxin in the age group 2 to 18 years.

Also read: Covaxin recommended for trial on 2-18 age group

Covaxin manufacturer Bharat Biotech had proposed to carry out the trial, which will be conducted on 525 healthy volunteers.

In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.

As rapid regulatory response, the proposal was deliberated by the SEC on May 11.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Suggested Articles